AIRLINK 217.98 No Change ▼ 0.00 (0%)
BOP 10.93 No Change ▼ 0.00 (0%)
CNERGY 7.55 No Change ▼ 0.00 (0%)
FCCL 34.83 No Change ▼ 0.00 (0%)
FFL 19.32 No Change ▼ 0.00 (0%)
FLYNG 25.15 No Change ▼ 0.00 (0%)
HUBC 131.09 No Change ▼ 0.00 (0%)
HUMNL 14.56 No Change ▼ 0.00 (0%)
KEL 5.18 No Change ▼ 0.00 (0%)
KOSM 7.36 No Change ▼ 0.00 (0%)
MLCF 45.63 No Change ▼ 0.00 (0%)
OGDC 222.08 No Change ▼ 0.00 (0%)
PACE 8.16 No Change ▼ 0.00 (0%)
PAEL 44.19 No Change ▼ 0.00 (0%)
PIAHCLA 17.69 No Change ▼ 0.00 (0%)
PIBTL 8.97 No Change ▼ 0.00 (0%)
POWERPS 12.51 No Change ▼ 0.00 (0%)
PPL 193.01 No Change ▼ 0.00 (0%)
PRL 43.17 No Change ▼ 0.00 (0%)
PTC 26.63 No Change ▼ 0.00 (0%)
SEARL 107.08 No Change ▼ 0.00 (0%)
SILK 1.04 No Change ▼ 0.00 (0%)
SSGC 45.00 No Change ▼ 0.00 (0%)
SYM 21.19 No Change ▼ 0.00 (0%)
TELE 10.15 No Change ▼ 0.00 (0%)
TPLP 14.51 No Change ▼ 0.00 (0%)
TRG 67.28 No Change ▼ 0.00 (0%)
WAVESAPP 11.29 No Change ▼ 0.00 (0%)
WTL 1.70 No Change ▼ 0.00 (0%)
YOUW 4.25 No Change ▼ 0.00 (0%)
BR100 12,191 Decreased By -205.8 (-1.66%)
BR30 36,583 Decreased By -764.3 (-2.05%)
KSE100 116,255 Decreased By -1331.9 (-1.13%)
KSE30 36,603 Decreased By -461.7 (-1.25%)

LONDON: AstraZeneca is paying up to $157 million, plus royalties, for an exclusive licence to develop and sell a set of pre-clinical COVID antibody therapies developed by RQ Bio, the London-based biotech said on Tuesday.

The experimental antibody therapies include those designed to target people with compromised immune systems - such as AstraZeneca’s own antibody cocktail, Evusheld, which is already approved in multiple countries, AstraZeneca recently signalled its interest in beefing up its roster of immune-focused therapies after carving out a new reporting unit in its quarterly reports entitled “Vaccines & Immune Therapies” that include its COVID products.

Pfizer Q1 revenues jump 77% to $25.7bn on Covid-19 vaccine

The company is banking Evusheld to partially offset its rapidly shrinking sales of its COVID vaccine, which was its second bestseller last year but has struggled to compete with rivals made by Pfizer and Moderna, and has hit setbacks with production, rare side-effects and relatively limited shelf life.

Comments

Comments are closed.